The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality

被引:854
作者
Taylor, PA
Lees, CJ
Blazar, BR [1 ]
机构
[1] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA
关键词
D O I
10.1182/blood.V99.10.3493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune regulatory CD4(+)CD25(+) cells play a vital role In the Induction and maintenance of self-tolerance and the prevention of autoimmunity. Recently, CD4 CD25(+) cells have been shown to be required for the ex vivo induction of tolerance to alloantigen via costimulatory blockade and to inhibit allogeneic skin graft rejection. Data presented here demonstrate that CD4(+)CD25(+) cells play an important role in graft-versus-host disease (GVHD) generation. Depletion of CN(+)CD25(+) cells from the donor T-cell inoculum or In vivo CD25-depletlon of the recipient before transplantation resulted in Increased GVHD mediated by CD4(+) or whole T cells in several strain combinations irrespective of the total body irradiation conditioning regime. The infusion of freshly purified donor CD4(+)CD25(+) cells modestly inhibited GVHD when administered in equal numbers with whole CD4(+) cells. Because CD4(+)CD25(+) cells only account for 5% to 10% of the total CD4(+) population, the administration of high numbers of fresh donor CD4(+)CD25(+) cells may not be clinically practical. However, we found that large numbers of CD4(+)CD25(+) cells can be obtained by ex vivo activation and expansion. Cultured CD4(+)CD25(+) cells, administered in equal numbers with CD4(+) T cells or CD25-depleted whole T cells, resulted in significant inhibition of rapidly lethal nGVHD. To our knowledge, this study is the first to demonstrate that activated, cultured CD4(+)CD25(+) cells can offer substantial protection in a relevant in vivo animal model of disease. These data have important ramifications for clinical bone marrow and solid organ transplantation. CD4(+)CD25(+) cells warrant consideration as an exciting new modality of cellular therapy for the inhibition of undesirable autologous and allogeneic responses. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3493 / 3499
页数:7
相关论文
共 32 条
  • [1] ANASETTI C, 1991, BONE MARROW TRANSPL, V7, P375
  • [2] Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation
    Asano, M
    Toda, M
    Sakaguchi, N
    Sakaguchi, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 387 - 396
  • [3] BLAISE D, 1991, BONE MARROW TRANSPL, V8, P105
  • [4] BONOMO A, 1995, J IMMUNOL, V154, P6602
  • [5] TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODY - A MULTICENTER PHASE-III STUDY
    CAHN, JY
    BORDIGONI, P
    TIBERGHIEN, P
    MILPIED, N
    BRION, A
    WIDJENES, J
    LIOURE, B
    MICHEL, G
    BURDACH, S
    KOLB, HJ
    LINK, H
    VERNANT, JP
    IFRAH, N
    RACADOT, E
    HERVE, P
    EHNINGER, G
    [J]. TRANSPLANTATION, 1995, 60 (09) : 939 - 942
  • [6] Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
    Carpenter, PA
    Pavlovic, S
    Tso, JY
    Press, OW
    Gooley, T
    Yu, XZ
    Anasetti, C
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (11) : 6205 - 6213
  • [7] Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood
    Dieckmann, D
    Plottner, H
    Berchtold, S
    Berger, T
    Schuler, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) : 1303 - 1310
  • [8] CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice
    Gao, QL
    Rouse, TM
    Kazmerzak, K
    Field, EH
    [J]. TRANSPLANTATION, 1999, 68 (12) : 1891 - 1897
  • [9] A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
    Groux, H
    OGarra, A
    Bigler, M
    Rouleau, M
    Antonenko, S
    deVries, JE
    Roncarolo, MG
    [J]. NATURE, 1997, 389 (6652) : 737 - 742
  • [10] Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor
    Harris, DT
    Sakiestewa, D
    Lyons, C
    Kreitman, RJ
    Pastan, I
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 (02) : 137 - 144